Merck KGaA has raised its full-year earnings outlook for the third time this year, driven by robust performance in its life science division and a slower-than-anticipated decline in sales of its multiple sclerosis drug Mavenclad.
The company now expects adjusted earnings to range between €6.2 billion and €6.4 billion ($7.1 billion), up from its previous upper-end forecast of €6.3 billion. Merck KGaA also increased its net sales guidance for the year, reflecting strong momentum in its lab-equipment business.
The latest upgrade comes as the company continues to benefit from sustained demand in its life science segment, which includes lab equipment and other research tools. The slower decline in Mavenclad sales has also provided a positive surprise, contributing to the improved outlook.